News
Fresenius doubles down on biosimilars with big WuXi alliance
Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.
News
Hutchmed, AZ file Orpathys for lung cancer on ESMO data
Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.
News
Inovio stock rises 2.5-fold on plasmid DNA drug approval
Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.
News
Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
News
AZ seeking $1.5bn in annual savings by end-2029
AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
